Supporting Information

Mirabamides E-H, HIV-Inhibitory Depsipeptides from the Sponge *Stelletta clavosa*

Zhenyu Lu,[†] Ryan M. Van Wagoner,[†] Mary Kay Harper,[†] Heather L. Baker,[‡] John N. A. Hooper,[§] Carole A. Bewley,[‡] and Chris M. Ireland*[,†]

*Department of Medicinal Chemistry, University of Utah, Salt Lake City, Utah, 84112, USA,Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, 20892-0820, USA,*and *Biodiversity Program, Queensland Museum, South Brisbane, Queensland, 4101, Australia*

List of Supporting Information

Figure S1. ^{1}H-NMR spectrum of mirabamide E (**1**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S2. ^{13}C-NMR spectrum of mirabamide E (**1**) in CD_3CN-H_2O (4:1)



Figure S3. HMBC spectrum of mirabamide E (**1**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S4. wgNOESY spectrum of mirabamide E (**1**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S5. ^{1}H-NMR spectrum of mirabamide F (**2**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S6. ^{13}C-NMR spectrum of mirabamide F (**2**) in CD_3CN-H_2O (4:1)



Figure S7. HMBC spectrum of mirabamide F (**2**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S8. wgNOESY spectrum of mirabamide F (**2**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S9. ^{1}H-NMR spectrum of mirabamide G (**3**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S10. ^{13}C-NMR spectrum of mirabamide G (**3**) in CD_3CN-H_2O (4:1)



Figure S11. HMBC spectrum of mirabamide G (**3**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S12. wgNOESY spectrum of mirabamide G (**3**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S13. ^{1}H-NMR spectrum of mirabamide H (**4**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S14. ^{13}C-NMR spectrum of mirabamide H (**4**) in CD_3CN-H_2O (4:1)



Figure S15. HMBC spectrum of mirabamide H (**4**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S16. wgNOESY spectrum of mirabamide H (**4**) in CD_3CN-H_2O (4:1) with 0.1% TFA-*d*



Figure S17-A. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (bottom) of the hydrolysis product of **1** in negative ion mode monitoring at 440 for 3-OHLeu residue.



Figure S17-B. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (bottom) of the hydrolysis product of **1** in negative ion mode monitoring at 382 for Ala residue.



Figure S17-C. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (bottom) of the hydrolysis product of **1** in negative ion mode monitoring at 426 for NMeThr residue.



Figure S17-D. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (bottom) of the hydrolysis product of **1** in negative ion mode monitoring at 412 for 3-OMeAla residue.



Figure S17-E. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (bottom) of the hydrolysis product of **1** in negative ion mode monitoring at 456 for ClHpr residue.



Figure S17-F. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (bottom)of the hydrolysis product of **1** in negative ion mode monitoring at 468 for 3,4-DiMeGln residue.



Figure S17-G. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (bottom) of the hydrolysis product of **1** in negative ion mode monitoring at 705 for Dab residue.



Figure S18. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (middle) of the hydrolysis product of **1** and the L-FDLA derivatives from the hydrolysates of papuamide A (bottom) in negative ion mode monitoring at 440 for 3-OHLeu residue and Newman projections analysis.



Figure S19. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (middle) of the hydrolysis product of **1** and the L-FDLA derivatives from the hydrolysates of papuamide A (bottom) in negative ion mode monitoring at 705 for Dab residue and Newman projections analysis.



(a) 2*S*,3*S*



(b) 2*S*,3*R*



Figure S20-A. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (middle) of the hydrolysis product of **1** and the L-FDLA derivatives from the hydrolysates of papuamide A (bottom) in negative ion mode monitoring at 468 for 3,4-DiMeGln residue and Newman projections analysis .





(a) 2*S*,3*S*



small



small



large

(b) 2*S*,3*R*



small



small



large

(c) 3*S*,4*R*



small



large



small

(d) 3*S*,4*S*



small



large



small

Figure S20-B. Ion chromatograms of the L-FDLA derivatives of the hydrolysis product of **1** (top) and the L-FDLA derivatives of the standard 2*S*, 3*S*, 4*R*-dimethylglutamine (middle) and 2*S*, 3*S*, 4*S*-dimethylglutamine (bottom) in negative ion mode monitoring at 468 for 3,4-DiMeGln residue



Figure S21. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (middle) of the hydrolysis product of **1** and the L-FDLA derivatives from the hydrolysates of papuamide A (bottom) in negative ion mode monitoring at 426 for NMeThr residue and Newman projections analysis





Figure S22. Ion chromatograms of the D/L-FDLA derivatives (top) and the L-FDLA derivatives (middle) of the hydrolysis product of **1** and the L-FDLA derivatives from the hydrolysates of mirabamide C (bottom) in negative ion mode monitoring at 456 for ClHpr residue.